Novel GABA_B receptor positive modulators: a patent survey

Bibliography

• Urwyler S, Gjoni T, Koljatic J, Mechanisms of allosteric modulation at GABA-B receptors by CGP7930 and GS39783: effects on affinities and efficacies of orthosteric ligands with distinct intrinsic properties. Neuropharmacology 2005;48:343-53
   PubMed Web of Science ®Google Scholar
• Couve A, Calver AR, Fairfax B, Unravelling the unusual signalling properties of the GABA-B receptor. Biochem Pharmacol 2004;68:1527-36
   PubMedGoogle Scholar
• Urwyler S, Mosbacher J, Lingenhoehl K, Positive allosteric modulation of native and recombinant GABA-B receptors by 2,6-di-tert.-butyl-4-(3-hydroxy-2,2-di-methyl-propyl)-phenol (CGP7930) and its aldehyde analogue CGP13501. Mol Pharmacol 2001;60:963-71
   PubMedGoogle Scholar
• Urwyler S. Allosteric modulation of GABA-B receptors. In: Bowery NG, editor, Allosteric receptor modulation in drug targeting. Informa Healthcare (Taylor & Francis), New York; 2006. p. 235-58
   Google Scholar
• Binet V, Brajon C, Le Corre L, The heptahelical domain of GABAB-2 is activated directly by CGP7930, a positive allosteric modulator of the GABA-B receptor. J Biol Chem 2004;279:29085-91
   PubMed Web of Science ®Google Scholar
• Schwartz TW, Holst B. Ago-allosteric modulation and other types of allostery in dimeric 7TM receptors. J Recept Signal Transduct Res 2006;26:107-28
   PubMed Web of Science ®Google Scholar
• Schwartz TW, Holst B. Allosteric enhancers, allosteric agonists and ago-allosteric modulators: where do they bind and how do they act? Trends Pharmacol Sci 2007;28:366-73
   PubMed Web of Science ®Google Scholar
• De Amici M, Dallanoce C, Holzgrabe U, Allosteric ligands for G protein-coupled receptors: a novel strategy with attractive therapeutic opportunities. Med Res Rev 2010;30:463-549
   PubMed Web of Science ®Google Scholar
• Pin JP, Prezeau L. Allosteric modulators of GABA-B receptors: mechanism of action and therapeutic perspective. Curr Neuropharmacol 2007;5:195-201
   PubMed Web of Science ®Google Scholar
• Frankowska M, Filip M, Przegalinski E. Effects of GABA-B receptor ligands in animal tests of depression and anxiety. Pharmacol Rep 2007;59:645-55
   PubMed Web of Science ®Google Scholar
• Jacobson LH, Cryan JF. Evaluation of the anxiolytic-like profile of the GABA-B receptor positive modulator CGP7930 in rodents. Neuropharmacology 2008;54:854-62
   PubMedGoogle Scholar
• Adams CL, Lawrence AJ. CGP7930: a positive allosteric modulator of the GABA-B receptor. CNS Drug Rev 2007;13:308-16
   PubMedGoogle Scholar
• Urwyler S, Pozza MF, Lingenhoehl K, N,N′-Dicyclopentyl-2-methylsulfanyl-5-nitro-pyrimidine-4,6-diamine (GS39783) and structurally related compounds: novel allosteric enhancers of gamma-aminobutyric acid B receptor function. J Pharmacol Exp Ther 2003;307:322-30
   PubMedGoogle Scholar
• Cryan JF, Kelly PH, Chaperon F, Behavioral characterization of the novel GABA-B receptor-positive modulator GS39783 (N,N′-dicyclopentyl-2-methylsulfanyl-5-nitro-pyrimidine-4,6-diamine): anxiolytic-like activity without side effects associated with baclofen or benzodiazepines. J Pharmacol Exp Ther 2004;310:952-63
   PubMed Web of Science ®Google Scholar
• Mombereau C, Kaupmann K, Froestl W, Genetic and pharmacological evidence of a role for GABA-B receptors in the modulation of anxiety- and antidepressant-like behavior. Neuropsychopharmacology 2004;29:1050-62
   PubMed Web of Science ®Google Scholar
• Wieronska JM, Wabno J, Froestl W, The antipsychotic action of novel orthosteric and allosteric positive modulators of GABA-B receptor in mice. Br J Pharmacol 2010; In press
   Google Scholar
• Dupuis DS, Relkovic D, Lhuillier L, Point mutations in the transmembrane region of GABA-B2 facilitate activation by the positive modulator N,N′-dicyclopentyl-2-methylsulfanyl-5-nitro-pyrimidine-4,6-diamine (GS39783) in the absence of the GABA-B1 subunit. Mol Pharmacol 2006;70:2027-36
   PubMedGoogle Scholar
• Orru A, Lai A, Lobina C, Reducing effect of the positive allosteric modulators of the GABA-B receptor, CGP7930 and GS39783, on alcohol intake in alcohol-preferring rats. Eur J Pharmacol 2005;525:105-11
   PubMedGoogle Scholar
• Liang JH, Chen F, Krstew E, The GABA-B receptor allosteric modulator CGP7930, like baclofen, reduces operant self-administration of ethanol in alcohol-preferring rats. Neuropharmacology 2006;50:632-9
   PubMed Web of Science ®Google Scholar
• Filip M, Frankowska M, Przegalinski E. Effects of GABA-B receptor antagonist, agonists and allosteric positive modulator on the cocaine-induced self-administration and drug discrimination. Eur J Pharmacol 2007;574:148-57
   PubMed Web of Science ®Google Scholar
• Frankowska M, Golda A, Wydra K, Effects of imipramine or GABA-B receptor ligands on the immobility, swimming and climbing in the forced swim test in rats following discontinuation of cocaine self-administration. Eur J Pharmacol 2010;627:142-9
   PubMed Web of Science ®Google Scholar
• Maccioni P, Pes D, Orru A, Reducing effect of the positive allosteric modulator of the GABA-B receptor, GS39783, on alcohol self-administration in alcohol-preferring rats. Psychopharmacology 2007;193:171-8
   PubMedGoogle Scholar
• Maccioni P, Fantini N, Froestl W, Specific reduction of alcohol's motivational properties by the positive allosteric modulator of the GABA-B receptor, GS39783: comparison with the effect of the GABA-B receptor direct agonist, baclofen. Alcohol Clin Exp Res 2008;32:1558-64
   PubMedGoogle Scholar
• Smith MA, Yancey DL, Morgan D, Effects of positive allosteric modulators of the GABA-B receptor on cocaine self-administration in rats. Psychopharmacology 2004;173:105-11
   PubMedGoogle Scholar
• Slattery DA, Markou A, Froestl W, Cryan JF. The GABA-B receptor-positive modulator GS39783 and the GABA-B receptor agonist baclofen attenuate the reward-facilitating effects of cocaine: intercranial self-stimulation studies in the rat. Neuropsychopharmacology 2005;30:2065-72
   PubMedGoogle Scholar
• Lhuillier L, Mombereau C, Cryan CF, GABA-B receptor-positive modulation decreases selective molecular and behavioral effects of cocaine. Neuropsychopharmacology 2007;32:388-98
   PubMed Web of Science ®Google Scholar
• Mombereau C, Lhuillier L, Kaupmann K, GABA-B receptor-positive modulation-induced blockade of the rewarding properties of nicotine is associated with a reduction in nucleus accumbens DeltaFosB accumulation. J Pharmacol Exp Ther 2007;321:172-7
   PubMed Web of Science ®Google Scholar
• Paterson NE, Vlachou S, Guery S, Positive modulation of GABA-B receptors decreased nicotine self-administration and counteracted nicotine-induced enhancement of brain reward function in rats. J Pharmacol Exp Ther 2008;326:306-14
   PubMed Web of Science ®Google Scholar
• Novartis AG; Pfannkuche H-J. Use of GABA-B receptor positive modulators in gastro-intestinal disorders. WO090731; 2003
   Google Scholar
• Novartis AG; Floersheim P, Froestl W, Guery S, Kaupmann K, Koller M. Pyrimidine derivatives for the treatment of GABA-B mediated nervous system disorders. WO136442; 2006
   Google Scholar
• Guery S, Floersheim P, Kaupmann K, Froestl W. Syntheses and optimization of new GS39783 analogues as positive allosteric modulators of GABA-B receptors. Bioorg Med Chem Lett 2007;17:6206-11
   PubMedGoogle Scholar
• Maccioni P, Carai MAM, Kaupmann K, Reduction of alcohol's reinforcing and motivational properties by the positive allosteric modulator of the GABA-B receptor, BHF177, in alcohol-preferring rats. Alcohol Clin Exp Res 2009;33:1749-56
   PubMed Web of Science ®Google Scholar
• Jacobson LH, Guery S, Froestl W, Gentsch C, In vitro and in vivo characterization of a novel GABA-B receptor positive allosteric modulator [Abstract 824.5]. 38th Society for Neuroscience Annual Meeting; 19 November 2008
   Google Scholar
• Addex Pharma S.A.; Riguet E, Campo B, Gibelin A, Mhalla K. Novel triazinedione derivatives as GABA-B receptor modulators. WO056257; 2008
   Google Scholar
• F. Hoffmann-La Roche AG; Malherbe P, Masciadri R, Prinssen E, Spooren W, Thomas AW. 4-(Sulfanyl-pyrimidine-4-yl-methyl)-morpholine derivatives and related compounds as GABA receptor ligands for the treatment of anxiety, depression and epilepsy. WO094828; 2005
   Google Scholar
• F. Hoffmann-La Roche AG; Malherbe P, Masciadri R, Norcross RD, Ratni H, Thomas AW. Quinoline as allosteric enhancers of the GABA-B receptors. WO048146; 2006
   Google Scholar
• F. Hoffmann-La Roche AG; Malherbe P, Masciadri R, Norcross RD, Prinssen E. 3-Methanesulfonylquinolines as GABA-B enhancers. WO128802; 2006
   Google Scholar
• F. Hoffmann-La Roche AG; Malherbe P, Masciadri R, Norcross RD, Ratni H, Thomas AW. Thieno-pyridine derivatives as GABA-B allosteric enhancers. WO063732; 2006
   Google Scholar
• F. Hoffmann-La Roche AG; Malherbe P, Masciadri R, Norcross RD, Prinssen E. 2-Hydroxy-propionic acid derivatives and 3-hydroxy-benzofuran-2-one derivatives with affinity for the GABA-B receptor. WO014843; 2007
   Google Scholar
• Malherbe P, Masciadri R, Norcross RD, Characterization of (R,S)-5,7- di-tert-butyl-3-hydroxy-3-trifluoromethyl-3H-benzofuran-2-one as a positive allosteric modulator of GABA-B receptors. Br J Pharmacol 2008;154:797-811
   PubMedGoogle Scholar
• Alker AM, Grillet F, Malherbe P, Efficient one-pot synthesis of the GABA-B positive allosteric modulator (R,S)-5,7-di-tert-butyl-3-hydroxy-3-trifluoromethyl-3 H-benzofuran-2-one. Synth Commun 2008;38:3398-405
   Web of Science ®Google Scholar
• Advani T, Hensler J, Cheng K, Stimulation of [35S]GTPgammaS binding by the GABA-B receptor agonists and positive modulators in different brain regions. Available from: http://www.fasebj.org/cgi/content/meeting_abstract/24/1_MeetingAbstracts/769.15
   Google Scholar
• AstraZeneca AB; Bauer U, Brailsford W, Chhajlani V, Egner B, Fjellstrom O, Gustafsson L, Mattson J, Nilsson K, Olsson T. Imidazole variants as modulators of GABA receptor for the treatment of GI disorders. WO001750; 2006
   Google Scholar
• AstraZeneca AB; Bauer U, Brailsford W, Gustafsson L, Saxin M, Svensson T. Imidazole derivatives for the treatment of gastrointestinal disorders. WO073298; 2007
   Google Scholar
• AstraZeneca AB; Bauer U, Gustafsson L, Saxin M. Imidazoles as GABA-B receptor modulators. WO073299; 2007
   Google Scholar
• AstraZeneca AB; Bauer U, Brailsford W, Gustafsson L, Svensson T. GABA-B receptor modulators. WO073300; 2007
   Google Scholar
• AstraZeneca AB; Bauer U, Brailsford W, Cheng L, Jonforsen M, Raubacher F, Schell P, Svensson T. Imidazole derivatives as modulators of the GABA receptor for the treatment of gastrointestinal disorders. WO130313; 2008
   Google Scholar
• AstraZeneca AB; Bauer U, Gustafsson L, Saxin M, Svensson T. Heterocyclic GABA-B modulators. WO073296; 2007
   Google Scholar
• AstraZeneca AB; Bauer U, inventor. Pyrazoles for the treatment of GERD and IBS. WO073297; 2007
   Google Scholar
• AstraZeneca AB; Cheng L, Karle M. Quinoline compounds having an activity against the GABA-B receptor. WO041904; 2009
   Google Scholar
• AstraZeneca AB; Cheng L, Holmquist S, Raubacher F, Schell P. Xanthine compounds having a positive allosteric GABA-B receptor modulator effect. WO130314; 2008
   Google Scholar
• AstraZeneca AB; Cheng L, Jonforsen M, Schell P. Pteridine compounds having activity on the GABA-B receptors. WO041905; 2009
   Google Scholar
• Johann Wolfgang Goethe-Universitat Frankfurt am Main; Duthey B, Pfeffer J, Boehncke W-H. Use of GABA-B selective agonists for treating inflammatory skin diseases. WO083992; 2008
   Google Scholar
• Gjoni T, Urwyler S. Receptor activation involving positive allosteric modulation, unlike full agonism, does not result in GABA-B receptor desensitization. Neuropharmacology 2008;55:1293-99
   PubMed Web of Science ®Google Scholar
• Gjoni T, Urwyler S. Changes in the properties of allosteric and orthosteric GABA-B receptor ligands after a continuous, desensitizing agonist pretreatment. Eur J Pharmacol 2009;603:37-41
   PubMedGoogle Scholar
• Gjoni T, Desrayaud S, Imobersteg S, Urwyler S. The positive allosteric modulator GS39783 enhances GABA-B receptor-mediated inhibition of cyclic AMP formation in rat striatum in vivo. J Neurochem 2006;96:1416-22
   PubMedGoogle Scholar
• Alstermark C, Amin K, Dinn SR, Synthesis and pharmacological evaluation of novel gamma-aminobutyric acid type B (GABA-B) receptor agonists as gastroesophageal reflux inhibitors. J Med Chem 2008;51:4315-20
   PubMed Web of Science ®Google Scholar
• Lehmann A, Antonsson M, Holmberg AA, (R)-(3-amino-2-fluoropropyl) phosphinic acid (AZD3355), a novel GABA-B receptor agonist, inhibits transient lower esophageal sphincter relaxation through a peripheral mode of action. J Pharmacol Exp Ther 2009;331:504-12
   PubMed Web of Science ®Google Scholar
• Bredenoord AJ. Lesogaberan, a GABA-B agonist for the potential treatment of gastro-esophageal reflux disease. I Drugs 2009;12:576-84
   PubMedGoogle Scholar
• Sternbach LH. The benzodiazepine story. J Med Chem 1979;22:1-7
   PubMed Web of Science ®Google Scholar